

Index

a

- ABJ-879 85
- Acacia aulacocarpa* 24
- acetylcholinesterase inhibitor 27
- achiral inhibitors 589–591
- Achromycin® 12
- A54145 complex 16
- acyclic epothilone analogs 113
- acyclic inhibitors 581, 582
- acyclovir 7
- acylation 47, 53, 56, 65, 236, 371, 376, 497, 519, 520, 525, 531
- acylfulvenes 483, 484
- acyl oxazolidinone 112
- adamantaplatensimycin 290
 - Nicolaou's synthesis 290
- adenine arabinoside (Ara-A) 7
- adenosine monophosphate (AMP) 573
- adenylosuccinate lyase 573
- adenylosuccinate synthetase (AdSS) 573
- aeruginosins 336, 586, 587
 - achiral inhibitors 589–591
 - aeruginosins 89A 336
 - aeruginosins 205A
 - structural elucidation 339
 - for thrombin 340
 - aeruginosins 298A
 - analogs 336–338, 344, 345
 - aeruginosins 205B
 - structural elucidation 339
 - synthetic aglycone of 340
 - for thrombin 340
 - constrained peptidomimetics 589
 - structure-based hybrids 586–589
 - truncated analogs 586–589
 - *in vitro* enzyme inhibitory activities of 338
- aglycone side chain 314
- AIDS-related Kaposi's sarcoma 128
- L-alanine 238
- Alder–ene reaction 549
- aldol-based build/couple/pair (B/C/P)
 - synthetic strategy 71
 - generating macrocycles 71
- 3-*trans*-alkyl azetidine lincosamides 263
- allyl ethers 465, 510
- allyl Grignard addition 518
- allylic alcohol 100, 106
- N-allylnorcodeine 228
- N-allylnormorphine 229
- allylsilane-containing spacer domain,
 - preparation of 528
- Alzheimer's disease 92, 476, 491, 497
 - phenotype model 492
- AM-2282. *see* staurosporines
- amaryllidaceae alkaloids 57
- Amberlyst resin 502
- amide bond, rigidification 352
- amikacin 568, 570
- amino acid–polyketide hybrids. *see* madindolines
- amino acid–sugar hybrids. *see* lincomycins; staurosporines
- 3-aminobenzoate analog 519
- 7-aminocephalosporanic acid 9
- 9-amino-CPT 197
- 14-amino-CPT 198
- 6-amino-2,2-dimethyl-3,4,6-trisubstituted-2H-1-benzopyran 65
- 20-aminomethyl-Epo B 100
- 6-aminopenicillanic acid 9
- anachelin H 488
- Andrographis paniculata* 47
- andrographolide-derived library 47
- Angelman syndrome 190
- angucyclines 457–462
 - anthracyclines 457
 - antitumor action 460
 - aquayamycin, total synthesis 462

- bioactivity 459, 460
- biomimetic approach, to construct 462
- biosynthesis 457, 458
- breast cancer resistance protein (BCRP) 460
- curved/linear framework 459
- landomycin A, total synthesis 463
- landomycin E 459
- occurrence 457, 458
- O→C-glycoside rearrangement 461
- [2+2]-photocycloadduct, gilvocarcin V and DNA 461
- polyketide-derived aromatic 461
- postmodification, nonclassical
 - angucyclines 460
- ravidomycin 459
- skeleton, biomimetic approach 463
- synthesis 460–462
- challenges 460
- urdamycinone B 462
- vineomycin A₁ 459
- anthracyclines 153, 457
 - curved/linear framework 459
- antibacterial spectrum 254–256
- antibiotics
 - mechanisms 271
 - resistance 255, 257, 271, 272, 295
- antifouling/antibacterial surface coatings 488
- anti-infective agents 5
- anti-MRSA drugs 253
- antiplasmodial agent 48
- antiproliferative activity
 - azathilone 109
 - bryostatin 1 508
 - 10,11-dehydro-Epo D 97
 - elomotecan 203
 - Epo A/B 84
 - of hypermodified analog 105
 - S-methoxy analog 108
- antisense approach 405
 - alternative splicing 406
 - antisense oligonucleotides (ASOs) 404
 - chemical design 406
 - single-stranded 405
 - drug discovery 404–406
 - endonuclease Argonaute 2 (Ago2) 405
 - hybridization 404, 405
 - microRNA (miRNA) pathway 405, 406
 - oligonucleotide 405
 - functional responses 405
 - RISC-loaded ASO 405
 - RNA degrading pathways 405
 - RNA/DNA heteroduplex 405
 - RNA-induced silencing complex (RISC) 405
 - RNA splicing 406
 - synthetic oligonucleotides 406
 - therapeutic intervention 406
 - toxic RNAs 406
 - 3'-untranslated region (3'-UTR) 405
- antisense oligonucleotides (ASOs) 406, 407
- antithrombin activity
 - aeruginosin natural products, analogs of 345
 - analogs of 345
 - pharmacophoric signature 342
- antitumor agents 5, 28, 77, 191, 479
- apoptosis 84, 113, 132, 194, 483, 487, 493, 509
- apple trees, phlorizin 302–304
- aquayamycin 462
- AR-67 201
- arabinoside (Ara-A) 7
- Ara-C 7
- Arg173 342
- argatroban 346
 - derived analogs 355
- A-ring functionalized analogs
 - end-game strategy 531
 - spacer domains, synthesis of 524
- O-aryl glucoside-based SGLT2 inhibitors 314
- aryl iodide 317
- aspartic acid 574
- AstraZeneca. *see* ximelagatran
- asymmetric allylic alkylation, hexasubstituted naphthalene 466
- asymmetric Brown allylboration 100
- asymmetric Keck allylation set C23
 - stereochemistry 505
- asymmetric Noyori hydrogenations 507
- ATP-binding site 24
- atropine 229
- augmentin 568, 569
- Augmentin® 10
- Aureomycin® 12
- AVE-1330A 9
- avermectin 377–380
 - vs. analogs 377, 378
 - ansatrienin A, biosynthesis 379
 - antiparasitic activity 379
 - avermectin pathway 380
 - engineering 380
 - best-performing mutants 380
 - C22–C23 alkene 380
 - cyclohexyl-CoA 379, 380
 - genes for production 380
 - enzyme aveC 380
 - overexpression 380
 - extensive screening, avermectin analogs 377

- glutamate-gated chloride channels (GluCl_s) 378
- identical analogs 379
- ivermectin (mectizan), semisynthetic avermectin 378
- used for 378
- labeling studies 379
- 2-methylbutyryl-CoA, priming unit 379
- natural avermectins 378
- *Onchocerca volvulus* 378
- PKS module 380
- precursor-directed biosynthesis 379
- doramectin 379
- primary metabolic pathways 379
- role 378
- *Streptomyces avermitilis* 377
- spontaneous mutant, ATC 53568 379
- wild type strain 380
- *Trichostrongylus colubriformis*
- infection 379
- *Wolbachia pipientis*, symbiont bacteria 378
- avermectin B_{1a} 591, 592
- avibactam (AVE-1330A) 10
- azabicyclononane (Abn) core structure
- banyasides A/B 344
- aza-Claisen reaction 53
- 4-aza-Epo D analogs 112
- aza-epothilones. *see* azathilones
- azathilones 109–111, 115
- azepane lincosamides
- *vs.* key pathogens, activity 264
- synthesis via ring-closing metathesis 263
- azetidine-2-carboxylic acid 262
- azetidine lincosamides 262
- azidothymidine (AZT) 7
- azithromycin 253, 254, 372, 373, 569, 570
- Aztreonam® 10, 11
- b**
- B0-A40926 14
- Bacillus cereus* 254
- backbone modifications, naturally occurring 424–426
- nuclease-mediated degradation, protection from 424
- phosphodiester 424
- backbone 424
- phosphorothioate
- modification (*see* phosphorothioate modification)
- bacterial fatty acid biosynthesis
- inhibitors 274
- pathway 273
- Bacteroides fragilis* 262
- bafilomycin A₁ 591–593
- macrocyclic analog 593
- semisynthetic ring-expanded analog 593
- structure 593
- banyaside A, structures of 343
- Barton–McCombie deoxygenation 287
- BAY59-8862 154
- BC-3205 20
- BC-3781 20
- BC-7013 20
- beauveriolide III 49
- belotecan 201, 569, 570
- benanomicin–pradimicin antibiotics (BpAs) (sugar–polyketide hybrids) 455–457
- bioactivity 455, 456
- family 456
- highly active antiretroviral therapy (HAART) 456
- HIV/AIDS 456
- lectins 455
- mannose recognition 455
- model, pradimicin A 457
- medical chemistry 456, 457
- occurrence 455
- regio/stereo-controlled access, BpAs synthetic intermediate 458
- SAR studies 455
- solid-state NMR study 455
- structure 456
- tetracyclic platform 458
- benzimidazole 62
- benzisothiazole 315
- benzodiazepinedione 28
- benzodiazepines 21, 22, 28
- benzomorphan 26, 27
- benzopyrans 22, 23
- benzothiazole 62, 102
- 4-benzyloxy-2-butanone
- kinetic enolate of 507
- biapenem 11
- biaxin 569
- bicyclic nucleosides 573, 574
- bicyclo/tricyclo-DNA (bc/tcDNA) class, nucleic acids 421, 422
- bcDNA-modified DNA oligonucleotides 422
- bcDNA scaffold 422
- structural variations 422
- bicyclo-DNA 422
- structure 422
- conformational restraint, DNA 421, 422
- 18/20-mer tcDNA gapmers 423
- PS-modified tcDNA gapmer ASOs 422

- therapeutic potential 422, 423
- RNA affinity improvement 422
- tcDNA modified duplexes 422
- sugar-phosphate backbone conformation 422
- x-ray crystallography studies 422
- tricyclo-DNA 422
- structure 422
- biolimus A9 28, 30
- biological niche 32
- biomimetic approach, of angucycline skeleton 463
- BIOS (biology-oriented synthesis)
 - approach 24, 27
 - "inside-out" approach 26
 - variation on 26
- bis-homo-avermectin B_{1a} 592
- biyouyanagin A 52
- β -lactamase inhibitor 569
- β -lactams 9–12, 259, 271, 576
 - analog design 576, 577
 - unnatural 578, 579
- blood coagulation cascade
 - linear peptides, aeruginosin family of 336
 - aeruginosin 298A 336–339
 - antithrombin peptide natural products 342–344
 - antithrombotic aeruginosins, analogs 344–346
 - dysinosins A–D 340–342
 - *Microcystis aeruginosa* 336–339
 - *Oscillatoria agardhii* 339, 340
 - schematic overview of 334
 - targeting 333, 334
 - thrombin structure 335
- BMS-247550 85
- BMS-310705 85
- BMS-753493 85
- BN80915 203
- BN-80927 204
- β -branching effect 346
 - aliphatic amino acid 344
- breast cancer resistance protein (BCRP) 460
- 2,4-bridged nucleic acids
 - C3'-endo sugar conformation 414
 - covalent conformational restriction, furanose ring 414
 - duplex thermal stability 414
 - LNA/LNA duplexes 414
 - structural studies 414
 - LNA-modified oligonucleotides 414
 - locked nucleic acid (LNA) 414
 - structural analogs 414
 - 2'-modified RNA analogs 414
 - pseudorotation cycle 414
- α -l-bridged nucleic acids 418–420
- α -l-amino-LNA 419
- analogs 419
- high-affinity recognition, RNA 419
- interesting properties 418, 419
- α -l-LNA/DNA chimeric oligonucleotides 418
- α -l-LNA, high-affinity RNA recognition scaffold 418
- modified oligonucleotides 419
- PS-modified ASOs 418, 419
- PS-modified α -l-LNA gapmer ASOs 419
- structures 419
- B-ring dioxolane analog 516–518
 - synthesis 518
- bromination 47
- 10-bromomethyl-11-demethyl-12-oxo calanolide A 65
- Brønsted acid 53
- bryostatins
 - analogs 513, 516, 530
 - accessibility to 508
 - A-ring functionalized 522–527
 - B-ring dioxane series of 527
 - bryostatins 1 476, 489, 491, 492, 495, 504, 508, 509, 523
 - intramolecular hydrogen-bond network of 504
 - semisynthetic analogs of 499
 - structure of 476
 - syntheses of 495
 - bryostatins 2/3/7
 - C7 functionality of 522, 523
 - syntheses of 493–496
 - bryostatins 9
 - syntheses of 495
 - bryostatins 16
 - syntheses of 494, 495
 - bryostatin total syntheses 493
 - total syntheses of 493, 494
 - bryostatin–vincristine combination therapy 491
 - family, of natural products 490
 - functional analogs 491
 - natural products 490
 - natural, total synthetic efforts 494
 - overview of 489
 - pharmacophore 500
 - protein kinase C (PKC) 492
 - scaffold, FOS application 496–498

- scaffold, initial pharmacophoric investigations 498–500
- synthetically accessible functional analogs design 500–508
- β -tubulin 84, 114, 115, 132, 143
- Bugula neritina* 489
- buprenorphine 225, 226, 235
- butorphanol 236, 237
- 7-*t*-butoxyiminomethyl camptothecin 200
- butyl azetidine 260
- tert*-butyl carbamate 109
- C**
- cabazitaxel 83, 135, 152, 153, 158
- calanolide A 64
- camptobell 201
- camptosar 196
- Camptotheca acuminata* 181, 182
- camptothecin 182
 - acts on eukaryotic Top 1 187–189
 - analogs 184
 - irinotecan 184
 - topotecan 184
 - approaches, synthesis of relevant intermediates 206
 - Anderson’s approach 206
 - Blagg and Boger’s strategy 206
 - Bosch’s approach 206
 - Chavan approach 206
 - Chavan’s cascade oxidative cyclization 206
 - Ciufolini’s intermolecular Michael addition 206
 - Comin’s approach 206
 - Curran and Nolan’s cascade 206
 - Fortunak’s approach 206
 - Henegar’s approach 206
 - Luo and Lu’s approach 206
 - Murata’s approach 206
 - Snieckus’s approach 206
 - biology activity 185, 186
 - CAPLUS database 185
 - chemistry 204
 - clinical investigations, derivatives 192, 193
 - clinical trials, derivatives 184
 - developments of modern chromatographic methods applied to 214
 - E-ring ketone derivatives 184
 - isolation 182
 - lactone and open carboxylate form 183
 - mechanism of action 183
 - new formulations and conjugates 191, 194
 - off-label investigation 190
 - preclinical profile 183
 - phase I clinical trials 183
 - prodrug/targeting 212, 213
 - prodrugs/polymer conjugates structures 213
 - properties 182
 - publications 184
 - S-phase-specific Top 1 poisons 186
 - structure-activity relationship 210, 211
 - total synthesis
 - (20*S*)-CPT, derivatives 210
 - (20*R*)-hCPT 209, 210
 - (20*R/S*)-hCPT 209, 210
 - nitro/amino-CPT 208
 - reactions used for 205
 - xenograft studies 211, 212
- C7 analogs 520–522
- C20 analogs 518–520
 - amide analogs 520
 - synthesis of 519
- capecitabine 83
- O-carbamoylation 56
- carbapenem 569
- carbaplatensimycin 287
 - Nicolaou’s synthesis 289
- carbocyclic compounds 59
- carbocyclic LNA analogs 417
 - duplex stabilizing properties 417
 - modified A-form DNA duplex 417
 - crystal structure 417
 - structure 417
- 1,3-*trans*- β -carboline 49
- carboxylic acid 106
- cardiovascular disease 497
- carfilzomib 484, 569, 570
- C-aryl glucoside series
 - aglycone modification of 315
 - analog synthesis 310
- cathepsin B 142
- CDA complex 17
- Cdc25A inhibitor 24, 25
- Cdc25A protein phosphatase 62
- C16-desmethyl Epo B 100
- C26-des-methyl recognition domain 505
 - second-generation route 506, 507
- C8 *gem*-dimethyl analogs 525
- cefotaxime 258
- cefovecin 12
- ceftaroline fosamil acetate 12
- ceftobiprole medocaril 12
- CEM-101. *see* solithromycin
- C13-enoate moiety, installation of 530
- cephalexin 9
- cephalosporin C 9

- cephalosporins 12
 - third-generation 258
 - c-ErbB2 24
 - certican 568
 - cerulenin 273, 274
 - cethromycin 19, 595
 - C7-functionalized analogs, PKC binding
 - affinities 523
 - C-glucosides
 - aglycone modifications 314–316
 - phlorizin, analogs of 309–314
 - sugar modifications 316–324
 - sugar-modified SGLT inhibitor clinical candidates 315
 - C-glycosides 461
 - Charette cyclopropanation, of *cis*-geraniol 95
 - chemically modified, marketed natural
 - products 568, 569
 - chemotherapy treatments 4, 212
 - chlorodysinosin A 341, 342, 586, 587, 588
 - Cleu residue of 346
 - hydrophobic interactions 588
 - stereoscopic view of 342
 - 4-chloro-3-(4-methoxybenzyl)phenyl side
 - chain 316
 - N-chlorosuccinimide (NCS) 67
 - chlortetracycline 381
 - Choi residue 344
 - chromatin maintenance region 1 exportin
 - (CRM1) 485
 - C7-hydroxy spacer domain, synthesis of 521
 - cilastatin 568, 569
 - ciprofloxacin 258
 - CKD602 201
 - clarithromycin (6-*O*-methylerythromycin)
 - 372
 - clavulanic acid 10, 568
 - clindamycin 251, 572, 594
 - comparison with other antibiotics 261
 - mechanism of action 253, 254
 - PK parameters 260
 - resistance 257, 258
 - side effects 258
 - pseudomembranous colitis 258
 - clindamycin hydrochloride 251
 - clindamycin palmitate 251, 254
 - clindamycin phosphate 252
 - C20, Luche reduction of 519
 - C6-modified lincosamines 262
 - C7-modified prodrugs 138
 - codeine 227
 - coenzyme A (CoA) thioester 367, 368
 - colchicine 127
 - combinatorial beauveriolide library,
 - synthesis 50
 - combinatorial biochemistry 17
 - combinatorial libraries, based on natural
 - products 23
 - community-acquired bacterial pneumonia
 - (CABP) 259
 - compound collections
 - with aza-heterocyclic scaffolds 66
 - alkaloid/terpenoid-inspired 67, 68
 - marinopyrrole A and corresponding library 66, 67
 - with carbocyclic core structures 60
 - illudin-inspired compound collection 60, 61
 - lapochol-inspired naphthoquinone collection 61
 - with decalin core structure 62, 63
 - with oxa-heterocyclic scaffolds 63
 - benzopyran-inspired compound collection 65, 66
 - calanolide-inspired compound collection 64, 65
 - carpanone-inspired compound collection 63, 64
 - conformational studies 114, 115
 - 2',4'-constrained MOE 415, 416
 - cMOE-modified gapmer ASOs 416
 - 2',4'-constrained ethyl BNA 415, 416
 - *R/S*-constrained ethyl class 416
 - crystal structure 416
 - *R/S*-constrained MOE 416
 - constrained MOE (cMOE) 415
 - gapmer ASOs 415
 - LNA-modified ASOs 415
 - LNA-modified oligonucleotides 415
 - LNA nucleotides 415
 - LNA, structural perspective 415
 - 2'-*O*-Me PNA 415
 - α , β -constrained nucleic acids (α , β -CNA) 423, 424
 - analogs 423
 - synthesis 423
 - conformational analysis, CNA family
 - members 423
 - constrain torsion angles 423
 - dioxaphosphorinane ring system 423, 424
 - duplex thermal stability 423
 - destabilizing effect 423
 - nucleotide dimers synthesis 423
 - proofreading DNA polymerases 423
 - structure 424
- contract research organizations (CROs) 596

- cordatolide A 64
 - Corey–Bakshi–Shibata (CBS) conditions 284
 - Corynebacterium diphtheriae* 254
 - cositecan 200
 - coumarins 348
 - CPT-11 196, 197
 - Crabtree catalyst 108
 - Crella spinulata* 45
 - cross-metathesis products 56
 - cryptic clusters 33
 - cryptothilone 1 113
 - C-seco* baccatin 158
 - C-seco*-taxoids 139
 - C13-substituted analogs, synthesis of 515
 - C9 *m*-substituted phenyl analogs 514
 - C9 *p*-substituted phenyl analogs 513
 - 5C-substituted pyrimidine analogs 427, 428
 - CpG (deoxycytidine-phosphate-deoxyguanosine) motifs 427
 - C5 thiazole pyrimidines 428
 - duplex stabilizing properties 428
 - improved 428
 - fundamental structural difference, DNA 427
 - vs. RNA 427
 - G-clamp 428
 - methylation 427
 - oligonucleotide therapeutics 428
 - PS-modified DNA 428
 - first-generation designs 428
 - reversible methylation 427
 - SAR studies 428
 - structures 427
 - Toll-like receptor 9 (TLR 9) 428
 - C-terminal arginine mimic (*l*-argol) 336
 - C26-trifluoro-*E*-9,10-didehydro-Epo D 85
 - cyanobacterium 339
 - cyclazocine 232, 237
 - cyclic amidine 586
 - cyclin-dependent kinase (cdk) 190
 - cyclopamine 545, 546
 - accessibility of 547, 549
 - degradation 553
 - modified derivatives 553, 555
 - prodrugs 555, 556
 - spectral data, analysis of 546
 - synthesis 548
 - cyclopropane carboxaldehyde 232
 - cyclopropane epothilone 106
 - cyclopropanes 570
 - cyclopropyl-Epo B analog 95
 - cyclopropyl epothilones 94
 - cyclorphan 232, 237
 - cyclotheonamide A
 - α -keto amide 344
 - structures of 343
 - cyanostilbenes 23
 - cytotoxicity 157, 158, 181
 - Top 1 inhibitors 190
- d**
- dabigatran 347
 - crystal structure 349
 - dabigatran etexilate 346
 - dabigatran–thrombin complex 348
 - dalacin 568, 570
 - dalbavancin 15
 - Danishefsky's diene, A-ring framework 502
 - dapagliflozin 301, 302, 313
 - daptomycin 16, 17, 253
 - daptomycin/A21978 complex 16
 - DB-67 201, 202
 - DB-91 201, 202
 - debenzylation 525
 - deforolimus 28, 30
 - 7-dehydrocholesterol reductase 547
 - 10,11-dehydro-Epo D 97
 - dehydrohomoplatencin 295
 - O-demethylation 232
 - 11-demethyl calanolide A 64
 - 11-demethyl-12-oxo calanolide A 65
 - 9-deoxo-9a-aza-9amethyl-9a-homoerythromycin. *see* azithromycin
 - 3-deoxy-2,3-didehydro-Epo A/B 91
 - N-derived drugs 3
 - des-A-ring analogs 513
 - synthetic accessibility of 514
 - des-A-ring spacer domains, synthesis 510, 511
 - des-C3-OH nanologs
 - *epi*-C3, binding affinities 504
 - Desert hedgehog (Dhh) protein 549
 - 20-desmethyl-20-methylsulfanyl-Epo B 100, 102
 - Dess–Martin periodinane 505
 - diabetes 497
 - diacetyl glycerol (DAG) 497
 - diazadione system 31
 - dibekacin 570
 - 9,10-didehydro-Epo B 85
 - trans*-9,10-didehydro-Epo D 98
 - Dieckmann cyclization 48, 49
 - Diels–Alder cycloaddition 56
 - Diels–Alder reaction 56, 205, 280, 283, 285, 286, 464
 - asymmetric 280, 283, 294
 - hetero using Danishefsky's diene 502, 506
 - intramolecular 206, 280, 284

- with siloxydiene 464
- dienophiles 56
- diffuse large B-cell lymphoma (DLBCL) 491
- diflomotecan 203
- difluorodocetaxel 142
- difluorotaxol 142
- Digenea simplex* 451
- digestive disorders, treatment 334
- dihydrobenzopyran 22, 23
- dihydrochalcone derivative, from apple bark 303
- dihydropyridone core motifs 352
- dihydropyridone thrombin inhibitors 353
- dihydrousambarensine 48
- dihydroxytetrahydroquinolinium moiety 488
- diketopiperazines 30
- N,N*-dimethylacetamide (DMA) 65
- 3-*N,N*-dimethylamino lincomycin 594, 595
- 2,3-dimethyl-benzimidazole 6-
 - carbaldehyde 106
- dimethyldioxirane (DMDO) 88
- 1,2-diol spacer domain 518
- directed sorting technique 59
- diversity-oriented synthesis (DOS) 44
- diverted total synthesis (DTS) 44, 485
- DJ-927 154, 155
- D*-leucine 586
- DNA alkylating agents 484
- DNA cleavage 478
- DNA gyrase 186
- DNA repair 186
- DNA/RNA duplexes
 - 3'-and 5'-phosphodiester linkages 410
 - A-type RNA/RNA duplexes 408
 - vs. B-type DNA/DNA duplexes 408
 - backbone torsion angle descriptors 408, 409
 - B-type DNA/DNA duplexes 408
 - C4'-C5' single bond 409, 410
 - conformational equilibrium 409
 - description 409
 - double helix, distinct grooves 408
 - furanose ring (*see* furanose ring)
 - *gauche* orientation 410
 - heterocyclic nucleobases 408
 - Newman projections, torsion angle ranges 408, 409
 - pseudorotation cycle 409
 - right-handed double helix 407
 - rotational equilibrium 410
 - stereoelectronic effects 410
 - structural features 407–410
 - sugar-phosphate backbone, conformation 408
- docetaxel 150–153
- domoic acid 452
- domoic acid 452
- doramectin. *see* avermectin
- doripenem 11
- DRF-1042 202
- Drosophila melanogaster* 546
- drosprenone. *see* yasmin
- drug discovery
 - antisense approach 404–406
- dysidiolide 22, 24, 62
- dysidiolide 25
- dysinosin A 586, 587, 588
 - crystal structures
 - stereoscopic view of 341
 - x-ray 341
- dysinosins 341
- e**
 - electron crystallography (EC) 114
 - elomotecan 203, 204
 - enantioselective allylation 106
 - enantioselective Robinson annulation 62
 - Enterobacteriaceae 258
 - Enterococcus faecalis* 254
 - Enterococcus faecium* 275
 - 19-*epi*-Avermectin A₁ 592
 - epidermal growth factor receptor (EGFR) 24
 - epimerization 48, 130, 134, 136, 281, 322, 370, 381, 483
 - Epo A 83, 84, 87, 113, 114
 - active *trans*-Epo A isomer 95, 103
 - conversion of Epo C into cyclopropyl 91
 - corresponding O3, O7-bis-formyl derivatives 91
 - epoxidation 92
 - retrosyntheses of 87
 - saturated 3-deoxy derivatives 91
 - total syntheses 86
 - tubulin-bound 114
 - tubulin–Epo A complex 84
 - Epo B 84–88, 90–92, 100–105, 108
 - corresponding O3, O7-bis-formyl derivatives 91
 - epoxidation 92
 - natural 85, 100, 102
 - pyridine-Epo B 100
 - retrosyntheses of 87
 - saturated 3-deoxy derivatives 91
 - total syntheses 86
 - epoch-making anticancer drug from nature. *see* Taxol

- Epo D 87, 88, 92, 93, 97, 98, 104, 105, 108, 109, 111
 - analog 104, 111
 - Danishefsky's second-generation synthesis 93
 - epothilone analogs, hypermodified 105
 - epothilone-cryptophycin hybrid 113
 - epothilones 83, 84, 113
 - first-generation syntheses 89
 - heterocycles attached to scaffold 102
 - natural, synthesis 86–90
 - nonnatural, synthesis and biological activity 90
 - fully synthetic analogs 92–114
 - semisynthetic derivatives 90, 91
 - resistance 85
 - side chain-modified analogs
 - growth inhibition cell lines 104
 - tubulin-bound conformation of 103
 - epoxidation 65, 86–88, 92, 95, 100, 105, 129, 505
 - of Epo D analog 103
 - eribulin 83, 482, 486, 568
 - ertapenem 11
 - ertugliflozin 302, 323, 324
 - ertugliflozin L-pyroglyutamic acid cocrystal
 - x-ray crystal structure of 323
 - erythromycin 69, 70, 259, 371–377, 594
 - acyltransferase domains 375
 - analogs 376
 - azithromycin (9-deoxo-9a-aza-9amethyl-9a-homoerythromycin) 372
 - biosynthesis, scheme 374
 - biosynthetic enzymes 372
 - β -carbon 375
 - oxidation levels 375
 - reduction stereochemistry 375
 - clarithromycin (6-O-methylerythromycin) 372
 - 6-dEB analogs 376
 - DEBS
 - genetic manipulation 375
 - heterologous expression 375
 - 6-deoxyerythromycin D 376
 - drawbacks 371
 - erythromycin A analogs 377
 - erythromycin/6-dEB synthase (DEBS) 372
 - *Escherichia coli* 375
 - feeding PKSs 374
 - function 372
 - *Haemophilus influenzae* 376
 - heterologous PKS construct 374
 - macrolide agents downside 372
 - megalomicin biosynthetic gene cluster 376
 - MIC₉₀ values, erythromycin analogs 373
 - multiple ribosomal mutations 372
 - mutasynthesis, fluorinated erythromycin analogs production 375
 - Pfeifer and coworkers contribution 377
 - precursor-directed biosynthesis 375
 - active erythromycin analogs 377
 - azide-containing erythromycin 376
 - *E. coli*-based 377
 - fluorine-containing erythromycin 376
 - key feature 375
 - resistance 372, 375
 - *Saccharopolyspora erythraea* 371
 - semisynthetic derivative 372
 - *in situ* acylation 376
 - *Streptomyces coelicolor* 375
 - genetically engineered strain 375
 - telithromycin, semisynthetic compound 372
 - Escherichia coli* 186, 275, 375
 - E* selectivity 110
 - ethnomedicine 181
 - 2-ethoxycarbonyl-3-aminopyrrole 66
 - ethyl acetoacetate
 - dienolate addition of 507
 - 7-ethyl,10-[1,4'-bipiperidine-carboxylate] camptothecin 196
 - Eunicella cavolini* 7
 - euphoriant 226
 - evernimicin (Sch-27899) 9
 - everolimus 28, 30
- f**
- filamentating temperature-sensitive protein Z (FtsZ) 157
 - FKBP12 (FK binding protein 12) 29
 - fluoroquinolones 259
 - 2'-fluoro RNA 413, 414
 - C3'-endo sugar conformation 413
 - fluorine 413
 - 2'-F modification of RNA (FRNA) 413
 - experiment results 413, 414
 - FRNA-modified duplexes 413
 - FRNA-modified nucleic acids 413
 - gapmer ASOs 413
 - Macugen, oligonucleotide aptamer 413
 - structure 412
 - vascular endothelial growth factor 1 (VEGF1) 413
 - N*-Fmoc-L-phenylalanine derivatives 49
 - FOS. *see* function-oriented synthesis (FOS)
 - Friedel–Crafts reaction 65
 - Fukuyama synthesis, K252a 447

functional bryostatin analogs. *See also*
 bryostatins, analogs
 – end-game strategy 503
 – initial preclinical investigations of 508, 509
 functional dynemicin A analog, steps, for FOS studies 478
 function-oriented synthesis (FOS) 44, 475
 – bistramide A 479, 480
 – design strategies 482
 – drug development 477
 – interplay of 477
 – overview of 476
 – pederin–psymberin chimaera 481
 – representative examples 478
 furano-Epo D analog 98
 furanose ring 408, 409
 – conformational equilibrium 409
 – envelope 409
 – twist conformation 409
 furaquinocins 462–467
 – asymmetric allylic alkylation,
 hexasubstituted naphthalene 466
 – biosynthesis 464
 – Diels–Alder reaction 464
 – furaquinocin C, Smith synthesis 465
 – furaquinocins A, B, and E, Trost
 syntheses 466
 – furaquinocins A, B, D, and H, total
 synthesis 466
 – gene cluster analyses 464
 – occurrence 462
 – quaternary center, 1,2-shift of aryl group 465
 – *Streptomyces* sp. KO-3988, isolated from 462
 – structure 464
 – synthesis 464–467
 – challenges 464
 furaquinocins A, B, D, and H 466
 furoindoline, unsuccessful alkylation 451

g

gem-dimethyl analogs 525
 generic analog strategy 501
 gentamicins 8
 gimatecan 184, 193, 200, 201, 202, 208
 Gli transcription factors 550, 551, 558
 Glu192 342
 glucose reabsorption 304
 – phlorizin-sensitive active transport
 system 305
 glucose transport 304
 glucose transporters (GLUTs) 301
 C-glucosides
 – SGLT2 inhibitor 310

– *in vitro* potency of 309
 O-glucosides 301
 – phlorizin, analogs of 306–309
 – SGLT2 inhibitors 308, 309
 glutamate-gated chloride channels
 (GluClCs) 378
 glutamine 287
 glycated hemoglobin (HbA_{1c}), discovery 313
 glycopeptide antibacterials 9, 13–16
 O-glycosides 441
 – naturally occurring 442
 – postmodification analogs, structure 442
 – structures 442
 glycosidic linkage
 – stereochemistry of 304
 gramicidin S 8
 Grignard reactions 63
 Grubbs catalyst 106

h

hadacidin, hybrid analogs 575
Haemophilus influenzae 376
 halaven 568
 halichondrin 83, 570
 Heck reaction 63
 hedgehog (Hh)
 – dependent tumors 552
 – protein 546, 547
 – signaling pathway 545, 547, 549–551
 – cancer involving, models 551, 552
 – inhibitors for treatment 552–555, 557
 – modulators 556–558
 – molecular basis 550
 heroin 227, 241
 – Wright's synthesis 227
 heteroatom-containing bicyclic lactams 351
 heterocycle modifications, naturally
 occurring 426–428
 – C5-substituted pyrimidine analogs (*see* C5-
 substituted pyrimidine analogs)
 – heterocycle-modified nucleosides 426
 – heterocyclic nucleobases 426
 – nucleobases, oligonucleotides 426
 – structures 427
 hetero-Diels–Alder reaction 506
 hexitol nucleic acids 420, 421
 – animal experiments 421
 – arabino 3'-fluoro hexitol nucleic acid
 (Ara-FHNA) 421
 – crystal structure 421
 – ara configuration 421
 – RNA affinity 421
 – C3'-endo conformation, RNA 420

- duplex destabilization 421
- electron-withdrawing groups, introduction 421
- FHNA-modified gapmer ASO 421
- fluoro hexitol nucleic acid (FHNA) 421
- crystal structure 421
- hexitol series 420
- modified oligonucleotides 421
- RNA affinity 421
- PS-modified ASOs 421
- structural relationship 420
- 2',4'-bridged nucleic acids 420
- 2'-modified RNA 420
- structure 420
- highly active antiretroviral therapy (HAART) 456
- high-pressure liquid chromatography (HPLC) 44, 46
- high-throughput screening (HTS) 43, 46
- hirsutine 48
- histone deacetylase inhibitors 580, 581
- HIV/AIDS 456
 - activation profile 492
 - eradication 497
 - latent viral reservoirs 532
 - expression 529
 - latent HIV expression
 - A-ring functionalized analogs/induction of 529
 - protease inhibitors 26
- homocamptothecin (hCPT) 184
- homocamptothecins 184, 203–204
- D-homo-cyclopamine 553, 554, 555
- A-ring-modified derivatives 555
- HOMO energy level 454
- homoplatensimide A 287
- hormone-resistant prostate cancer 83
- host–microbe interactions 32
- Hückel's aromaticity rules 31
- Hudlicky's synthetic route, toward methylhaltrexone 233
- hybrid natural product 441
- hybrid structures, and acyclic analogs of epothilones 112, 113
- Hycamtin® 194, 195
- hydantocidin 573–576
 - hybrid analogs 575
- hydantocidin monophosphate 574
- meta-hydrogen-bond acceptor 513
- hydrophobic amino acid (D-Leu) 336
- hydroxyalkoxychromanes 65
- hydroxyangustine 49
- 14-hydroxydihydromorphinone 232

- 14-hydroxydihydromorphinans 232
- 5-(2'-hydroxy ethoxy)-20(S)-camptothecin 202
- hydroxyl benzothioephene 355
- 10-hydroxyl, 9-[(dimethylamino)methyl]-camptothecin 194, 195
- hydroxymethylacylfulvene (HMAF) 483
- Hypericum chinense* 51

i

- IC₅₀ values
 - analogs of aeruginosin natural products 345
 - C-glucoside and sugar-modified SGLT inhibitor 315
 - chemically modified and truncated analogs of oscillarin 588
 - congeners of platensimycin and platencin 288
 - phenyl, phenol, and pyridine N-oxide thrombin inhibitors 354
 - side chain-modified epothilone analogs 104
 - *in vitro* enzyme inhibitory activities of aeruginosins 338
- idarubicin 569, 570
- IDN5109 154
- imipenem 568, 569
- Indian hedgehog (Ihh) protein 549
- indinavir 64
- indole alkaloids 441
 - structures 442
- indolo[2,3-*a*]quinolizidine framework 48
- indoloquinolizines 48, 49
 - from readily accessible substrates, cascade synthesis 54
- interleukins 450
- inverse electron demand Diels–Alder (IEDDA) cycloaddition 64
- irinotecan 184, 190, 196
 - chemical modifications, improving therapeutic index 197
 - synthesis of 207
- ISN 5109 154
- isopavines 237
- isoplatensimycin 292
 - Lee's synthesis of 292
- isoxazole-containing derivative 85
- ixabepilone 90
- ixempra 568, 570

j

- jervine 546, 547
- Jevtana® 153
- Julia olefination procedure 494

k

- kainic acid 452
- kainoids (amino acid–terpene hybrids) 451–455
 - analogs 452
 - bioactivity 451–453
 - biosynthesis 453
 - conformations with glutamate, receptors 454
 - *Digenea simplex* Kaininso, isolated from 451
 - domoic acid biosynthesis 453
 - HOMO energy level 454
 - interactions, with glutamate receptor 455
 - kainic acid
 - Opolzer enantioselective total synthesis 451–455
 - practical synthesis 454
 - medicinal chemistry 453–455
 - molecular modeling 454
 - neuroexcitatory activity 454
 - neurogenic activities 452
 - occurrence 451
 - orthogonal bioactivity 454
 - SAR studies 453, 454
 - structure 452
 - synthesis 453
- Karenitecin® 200
- Keck–Yu pyran annulation reaction 496
- ketek 569
- β-ketoesters 512
- ketone, olefination of 528
- KOS-862 85, 92
- KOS-1584 85
- kyprolis 569, 570

l

- β-lactam antibiotics 8, 10, 477, 576
- γ-lactams 52, 53
- lactam thrombin inhibitors 353
- lactol, oxidation 322
- landomycin A 463
- lapachol 61
 - naphthoquinone collection inspired by 61
- largazole, GI₅₀ values 483
- larotaxel 153, 154
 - with carboplatin 154
 - cisplatin combination 154
- laudanum 226
- lectins 455
- leishmania* 61
- Leu dihedral angle 342
- levallorphan 230

- Lewis acid 73, 232, 280, 311, 318, 461, 465, 552, 554
- Librium^(R) 22
- ligand–protein interactions 513
- lincomycins 251, 254, 448, 449, 572
 - amino acid moiety, biosynthesis 449
 - bioactivity 448
 - biosynthesis 448
 - clinically used analogs 448
 - gram-positive bacteria, inhibition 448
 - interaction with, nucleotide unit 23S tRNA 449
 - medical chemistry 449
 - occurrence 448
 - *Streptomyces lincolnensis*, isolated from 448
 - structure 448
- lincosamides 251, 252, 258
 - next-generation 259
- lincosaminides 570
- linezolid 254, 272, 275, 595
 - profiles 276
- lipopeptide 9
 - antibacterials 16–18
- Lipotecan® 195
- Listeria monocytogenes* 254
- lomaitivcin derivatives 487
- lurtotecan 199
- Lys–X bond 335

m

- MAC-323 155
- macrocyclic
 - compound collections 68
 - analogs of erythromycin A 69, 70
 - macrocycles and medium-sized rings, strategy for synthesis 71
 - macrospheptide A-inspired 68, 69
 - inhibitors 582, 583
 - natural products 68
 - taxol analog 113
- macrolactone 69, 86, 106, 493, 592
- macrolactonization 88, 106
- macrolides 9, 18, 19, 69, 570
- macrospheptides A and B 68, 113
- madindolines 449–451
 - bioactivity 450
 - furoindoline alkylation 451
 - interleukin-6 450
 - inhibition 450
 - madindolines A 449, 450
 - madindolines B 449, 450
 - occurrence 449, 450
 - second-generation total syntheses 452

- *Streptomyces* sp. K93-0711, isolated from 449
- synthesis 451
- – challenges 451
- malayamycin A 573
- N-malayamycin A 573
- Malus* species 303
- Mannich–Michael reaction 49
- mannose recognition model, of pradimicin A 457
- Mappia foetida* 58
- marine bryozoan 489
- marinopyrrole A 66
- mass spectrometry (MS) 44
- 5'-Me-LNA 416, 417
 - duplex stabilizing properties 416, 417
 - S-5'-Me-LNA gapmer ASO 416
 - structure 417
 - torsion angle γ 416
- meperidine 228, 229
- meta-chloroperbenzoic acid 88
- meta-chloroperoxybenzoic acid 65
- methadone 229, 230
- methicillin-resistant *Staphylococcus aureus* (MRSA) 10, 12, 13, 16, 253, 272, 276, 290, 292, 296, 382
- methyl 5-chloro-5-oxovalerate 507
- methyldihydromorphinone 228
- methyl-4,4-dimethoxybutyrate 49
- O-methyl lactol 312
- methylthiolincosaminide 251
- metopon 228
- microbial secondary metabolites, as
 - antibacterial drugs 8, 9
- microRNA (miRNA) pathway 405, 406
- microtubules (MTs) 83
- microtubule-stabilizing agents (MSA) 83, 159
- milataxel 155
- Minocin® 12
- mitomycin c 442
 - biosynthesis 443
 - mode of action 443
 - structure 442
 - usage 442
- Mitsunobu conditions 106
- Mitsunobu reaction 521, 549
- 2'-modified RNA 411
 - advantages 411
 - analogs 411
 - autocatalytic hydrolysis prevention 411
- modithromycin (EDP-422) 19
- molecular dynamic (MD) modifications 29
- monobactam nucleus 11
- monoclonal antibodies (mAb) 159
- morphine 26, 27, 225, 226
 - analogs 240–243
 - codeine 227
 - N-cyclopropyl-substituted compounds 231, 232
 - deoxy morphinans 241
 - early-stage semisynthetic drugs 228
 - enantiomer 226
 - vs. meperidine 229
 - papaverine 227
 - pharmacology 238–240
 - properties 225
 - receptor binding interactions for natural and unnatural 243
 - structure-activity relationship 240–244
 - structure elucidation 227, 228
 - tetracyclic morphinans 230
 - thebaine 227
 - tricyclic benzomorphans 230–232
 - Wright's synthesis of heroin 227
- morphinomimetics 579, 580
- MRP7 efflux pump 85
- mTOR (mammalian target of rapamycin) 29
- multi-drugresistant (MDR) cancer cell lines 84
- Mulzer's preparation 486
- myalgia 491
 - dose-limiting toxicity 491
- Myc oncogene expression 509
- Myxococcus xanthus* 97
- n**
- nakijiquinone 25
- nakijiquinone C 24, 25
- nalbuphine 225, 226, 237
- nalorphine 229, 230
- naloxone 225, 226, 232, 237
- naltrexone 225, 226, 232, 233, 237
 - semisynthetic routes toward 233
- namitecan 202, 203, 208
 - synthesis 208
- N- and S*-linked materials 4
- nanoparticle-associated albumins 3, 4
- NAPAP 347, 348, 354
 - dabigatran discovery from 348
- naphthalene 62, 464, 465
 - hexasubstituted 466
- naphthoquinones 61, 462, 464
- natural macrocycle 113
- natural product-derived compounds,
 - semisynthetic libraries 46, 47
- natural product-inspired compounds, synthetic
 - libraries of 47, 48

- natural product libraries, prefractionated 45, 46
- marine products library, approach to generate 46
- natural thiazole heterocycle 100
- natural yohimbine alkaloids 49
- nazumamide A 342
- structures of 343
- N-desmethyl-topotecan 195
- necrosis 113
- Negishi cross-coupling reaction 50, 112
- Neisseria gonorrhoeae* 18
- neomycin 8
- neurogenic activities 452
- neuropathic pain 497
- new chemical entity (NCE) 43
- Nicolaou's synthesis 102
- cyclopropyl-Epo B analog 94, 95
- 9-nitro-CPT 197
- NMR spectroscopy 114, 115
- noncovalent thrombin inhibitors 347
- nonproteinogenic
- (S)-3-carboxymethyl-L-proline 451
- non-small cell lung cancer (NSCLC) 105, 128, 133, 151, 155, 200
- norbenzomorphans 27
- noroxymorphone 232
- nor-platencin, Snider's synthesis 294
- Nothapodytes foetida* 58
- novel structures, from natural sources 31–33
- novolimus 28–30
- nuclear magnetic resonance (NMR) 44
- nuclear Overhauser effect (NOE) study 56
- nucleic acid polymers
- coding regions (exons) 403
- deoxyribonucleic acid (DNA), structure 404
- genetic information 403
- intergenic regions (introns) 403
- natural uses 403, 404
- ribonucleic acid (RNA), structure 404
- RNA interference (RNAi) mechanisms 403
- role 404
- nucleic acid–protein interactions 429
- nucleosides 4, 6, 426, 572–576
- O**
- octahydroindole core residue (I-Choi) 336
- octosyl acid A 574
- 10-OH-CPT (10-hydroxy-camptothecin) 194
- olefin metathesis analogs 517
- oligonucleotide drugs 406
- antisense oligonucleotides (ASOs) 406, 407
- objectives accomplished 407
- medicinal chemistry approach 406, 407
- natural nucleic acids 407
- intrinsic pharmacokinetic properties 407
- RNA-based ASOs 407
- RNA/RNA duplexes 407
- oligonucleotides, binding affinity
- ASO affinity, strategy to improve 411
- C3'–endo conformation, furanose ring 410, 411
- structural mimicry of RNA 410–421
- 2'-O-Me RNA 411, 412
- antisense mechanism 411
- ASOs 411
- design 412
- 2'-deoxy-2'-fluoro RNA (2'-F RNA), conjunction with 412
- gapmer ASO 411
- advantage 411
- structure 412
- RISC complex 412
- structure of analogs 412
- 2'-O-methoxyethyl RNA 412, 413
- ASOs containing MOE nucleotides 413
- conformational equilibrium, furanose ring 412
- first generation PS DNA 413
- MOE RNA duplex 413
- crystal structure 413
- MOE side chain, restricted rotation 413
- PS DNA-modified ASOs 413
- RNase H-based antisense applications 413
- structure 412
- survival of motor neuron (SMN) protein 413
- Omphalotus illudens* 60
- opioids 225
- derivatives 226
- early-stage semisynthetic opiates 229
- receptor 243
- Oppolzer enantioselective total synthesis
- kainic acid 453
- Orathecin® 197
- organolithium, from aryl bromide 318, 322
- oripavine 235
- oritavancin 13, 15
- ortataxel 154
- oscillarin 586, 587
- analogs 588
- cocrystal structure 587
- structural elucidation 339
- Oscillatoria agardhii* 339
- O-silylation 58

oxazolidinone ketolide mimetics 595, 596
 oxepane natural product-inspired collection 56

P

- paclitaxel. *see* taxol
 pactamycin analogs 583–586
 palladium-catalyzed coupling reactions 50
 papaverine 227
Papaver somniferum 43
 parallel synthesis 59
 Parikh–Doering oxidation 505
 pateamine A scaffold 482
 Pd-catalyzed intramolecular asymmetric alkylation 339
 Pearlman's catalyst debenzylated C26 502
 penicillin G 8, 272, 576, 577
 penicillins 8, 9, 252, 257, 271, 272, 577
 pentazocine 231, 232, 240
 peptidic thrombin inhibitors
 – proline analogs 350
 Pgp170 drug efflux pump 106
 Pgp-mediated drug efflux 106
 pharmacokinetic (PK) properties 316
 pharmacophore modeling 114, 115
 phenol N-oxide thrombin inhibitors 354
 phenyl N-oxide thrombin inhibitors 354
 D-Phe–Pro–Arg–chloromethyl ketone (PPACK) 335
 phlorizin 301, 302
 – analogs of 306–309
 – C-glucosides 309–314
 – O-glucosides 306–309
 – from apple trees 302–304
 – diabetes 306
 – in diabetic animal models 306
 – isolation of 301
 – mechanism of action 304–306
 – SGLTs 306
 – x-ray crystal structure of 304
 phloroglucinol (1,3,5-trihydroxybenzene) ring 304
 phorbol ester (PE)
 – C20 hydroxyl 498
 – tumor promoters 496
 phosgene 48
 – mediated cyclization 49
 phosphate ester prodrug 251
 phosphatidylinositol 3-kinase (PI3K) 29
 phosphorothioate modification 425, 426
 – animal experiments 426
 – morpholino oligonucleotides 426
 – neutral phosphorodiamidate linkage 426
 – oligonucleotide backbone modifications 425
 – structure 425
 – phosphorothioate backbone modification 425
 – phosphorothioate linkage 425
 – features 425
 – phosphorothioate-linked nucleotide dimers 425
 – PS modification, bacteria 425
 – advantages 426
 – PS-modified ASOs 426
 – RNase H-mediated cleavage, complementary RNA 425
 – second-generation designs 426
 physostigmine 27
 Pictet–Spengler reaction 49, 53
 pipecolamides 262
 pirlimycin 252, 254, 262
 PIRSUE® 252
 PKC. *see* protein kinase C (PKC)
Plakortis quasiamphiaster 45
 platencin 271, 272
 – analogs 287, 290, 292, 294, 295
 – antibacterial activity against 275
 – bioactivities 272
 – biosynthesis 275
 – congeners 288, 289
 – discovery 272
 – mode of action 276
 – profiles 276
 – structures 275
 – total and formal syntheses 283–286
iso-platencin 295
 platensic acid 274
 platensimycin 271, 272
 – analogs 287, 290–295
 – antibacterial activity against 275
 – bioactivities 272
 – biosynthesis 275
 – congeners 288, 289
 – crystal structure of (ec)FabF(2GFX) 277
 – discovery 272
 – interactions with ecFabF(2GFX) 277
 – mode of action 276
 – profiles 276
 – as selective inhibitor of FabF 275
 – structures 275
 – total and formal syntheses 278–283
 platensinic acid 274
 pleuromutilin 20
 – derivatives 19, 20
 pleuromutilins 9
Pleurotus mutilus 20
Pleurotus passeckerianus 20

- plicamine 57, 58
 - total synthesis 57
 - polar N-terminal acyl group (D-Hpla) 336
 - polycyclic alkaloid ring systems, cascade synthesis 55
 - 7-polyethylene glycol 138
 - polyketide-based macrocycles 92–108
 - polyketide biosynthesis
 - ACP-bound α,β -unsaturated thioester 370
 - acyl carrier protein (ACP) 368
 - acyltransferase (AT) domain 368
 - altered stereochemistry 370
 - chain elongation, decarboxylative Claisen 368
 - coenzyme A (CoA) thioester 367, 368
 - curacin PKS 370
 - dehydratase (DH) domain 368, 370
 - x-ray crystal structure 370
 - enoylreductase (ER) domain 369, 370
 - epimerization 370
 - ketoreductase (KR) domain 368
 - reduction 370
 - responsible for 368
 - selectivity 370
 - ketosynthase/chain length factor (KS/CLF) heterodimer 370
 - malonyl-charged ACP 368
 - mechanism 367–371
 - natural products 368
 - polyketide chain length, control 371
 - polyketide subunit, newly formed 368
 - oxidation state 368
 - polyketide synthases (PKSs) 367
 - post-PKS transformations 371
 - thioesterase (TE) domain 370
 - type I PKSs 367, 368
 - chain elongation initiation 369
 - oxidoreductive modification 369
 - type II PKSs 367, 370
 - chain elongation 371
 - α,β -unsaturated polyketide 370
 - polyketide synthases (PKSs) 367
 - multifunctional bacterial subclasses 367
 - type I 367, 368
 - type II 367
 - polyketide–terpene hybrids. *see* furaquinocins
 - P2 pyridone motif 352
 - practical synthesis, of kainic acid 454
 - precursor-directed biosynthesis 375, 376
 - active erythromycin analogs 377
 - azide-containing erythromycins 376
 - doramectin 379
 - fluorine-containing erythromycins 376
 - key feature 375
 - P2 replacement strategies 349
 - Prins-cyclization reaction 528
 - Prins-driven macrocyclization 528
 - strategy 527
 - toward B-ring pyran analogs 527–530
 - privileged structures 21
 - proflavine 271, 272
 - programmable enantioselective
 - one-pot synthesis, of complex molecules 72
 - proline analogs, as peptidic thrombin inhibitors 350
 - D-prolinol analog 350
 - prontosil 271, 272
 - Propionibacterium acnes* 254
 - 4-propylpipercolic acid 259
 - L-pro residue 344
 - protein kinase C (PKC) 24, 483, 492, 497, 498, 508, 522
 - analog affinity 532
 - B-ring pyran bryostatin analogs, *in vitro* antiproliferative activity of 530
 - C7-functionalized-analogs 526
 - diacylglycerol-regulated, schematic of 492
 - GFP-tagged conventional isoform PKC β 1 525
 - HIV latency, J-Lat cell line model of 532
 - isoforms, therapeutic indications 493
 - Nishizuka's discovery of 497
 - protein kinase C δ (PKC δ) 479, 525
 - protein-protein interactions 27, 28
 - protein structure similarity clustering 62
 - Proteolix company 484
 - pseudomembranous colitis 258
 - Pseudomonas aeruginosa* 11
 - pure natural products, libraries of 46
 - purine 6, 24, 102, 410, 421
 - pyrazinone motif 353
 - pyrazinone thrombin inhibitors 354
 - pyridine N-oxide thrombin inhibitors 354
 - pyridinium chlorochromate (PCC) 56
 - pyridinium *p*-toluenesulfonate (PPTS) 69
 - pyridone thrombin inhibitors 352, 353
- q**
- quantamycin 572, 573
 - Quinn's approach 26
 - quinoline-based Epo B analogs 103
 - quinoxalinone scaffold 355
- r**
- ramoplanin 16
 - ramoplanin A2 17

- Raney nickel 549
 rapamycin 29
 RCM-based macrocyclization 88
 “N-related” approved drugs 2
 retapamulin 20
 rhizoxins 32
 rimactane 568, 570
 ring-closing *alkyne* metathesis (RCAM) 88
 ring closing olefin metathesis 88
 ring-expanded BNA analogs 417, 418
 – aza-ENA 24-modified oligonucleotides 418
 – bicyclic system 417
 – BNA scaffold 418
 – carba-ENA analogs 418
 – cENA analogs 418
 – – 2',4'-bridge 418
 – Epi-cENA 417
 – ethylene nucleic acid (ENA) 417
 – oxyamino BNA 418
 – structures 418
 RNA/RNA duplexes 407
 root mean square deviation (RMSD) 497
 Roskamp homologation 513
 RP 56976 150–153
 RPR109881 153, 154
 RPR 116258A 153
 rubitecan 197, 198
 Ru-catalyzed Alder-ene/oxy-Michael
 sequence 495
- S**
Saccharopolyspora erythraea 371
 sagopilone 85, 105
 Salinispora species 32
 salinosporamide A 33, 385–387
 salinosporamides 385–391
 – additional analogs 390
 – altered C5 substituents, effects of 390
 – amino acid 62 389
 – – biosynthesis 390
 – biosynthetic compounds, biological
 activities 389
 – bromosalinosporamide 388
 – chloroethylmalonyl-CoA 388
 – – biosynthesis 388
 – decarboxylative chain elongation 387
 – engineering analogs, major focus 389
 – feeding studies 387
 – fluorosalinosporamide A 388
 – inhibitor of 385, 386
 – iodosalinosporamide 388
 – oxygenase SalD 390
 – *Salinispora tropica*, isolated from 385, 388
 – salinosporamide A 386
 – – biosynthesis 387
 – – biosynthesized from 387
 – – mode of action 386
 – salinosporamide synthase 391
 – semisynthetic compounds, biological
 activities 389
 – therapeutic potential 386
 – used as 391
 – x-ray crystal structures 386
 salvansan 272
 salvinorin A 243
 – analogs 243
 saponification 47, 286
 SB-T-101131 154
 Sch-27899 8
 SCID mouse models 488
 Scopus database 29
 semisynthetic 3-*N,N*-dimethylamino
 lincomycin analog 594
 separation technologies 44
 sergliflozin 301, 302
 sergliflozin etabonate 307, 308, 312, 313
Shigella dysenteriae 12
 silatecan 201
 sirolimus 29, 30
 Smith–Lemli–Opitz syndrome 547
 Smith synthesis, furaquinocin C 465
 Smoothened (Smo) protein 547, 550, 558
 SN-38 197
 – synthesis 207
 sodium-glucose cotransporter 2 (SGLT2)
 – inhibition 301
 – – PKPD model 320
 – – T2DM treatment 302
 – inhibitors 313
 – phlorizin 306
 sodium-glucose cotransporters 305
 solid-phase extraction (SPE) 44
 solid-phase synthesis
 – alkaloid/terpenoid-inspired compound
 collection 68
 – carpanone-inspired compound
 collection 63, 64
 – compound collection having decalin core
 structure 62
 – lamellarin-based collection 51
 – macrospheptide A and analogs 69
 – substituted benzopyran compound
 collection 66
 solid-phase techniques 48–50
 solid-supported reagents, and scavengers
 55–58

- oxepane natural product-inspired collection 56
 - solithromycin 18, 19
 - solution-phase synthesis
 - biyouyanagin-inspired compound collection 51
 - solution-phase techniques 50–55
 - Sonic hedgehog gene 547
 - Sonic hedgehog (Shh) protein 547, 549
 - Sonogashira reaction 63
 - Sorangium cellulosum* 84
 - spacer domain function 514
 - C3 hydroxyl, exploration of 504
 - coupling of 510
 - fragments 530
 - hydroxyester 515
 - synthesis of 515, 516
 - spasmolytic drugs 228
 - spirocyclization 317
 - sponge-derived nucleoside link to drugs 5
 - spongothymidine 7
 - spongouridine 6
 - S^{*}-related natural product 5–7
 - ST1481 200
 - ST1968 202
 - Staphylococcus aureus* 9, 271
 - antibiotics effective against 273
 - resistance to penicillin 271
 - staurosporines 444–447
 - antimicrobial effect 444
 - ATP, structural comparison 446
 - bioactivity 445
 - biosynthesis 446
 - cocrystal 445
 - Fukuyama synthesis, K252a 447
 - medical chemistry 447
 - occurrence 444, 445
 - protein kinase activity, deregulation 445
 - related compounds 445
 - structure 444, 445
 - synthesis 446, 447
 - challenge 446
 - Stille coupling 102
 - Streptomyces aureofaciens* 381
 - Streptomyces avermitilis* 377
 - Streptomyces coelicolor* 375
 - Streptomyces lincolnensis* 251, 448
 - Streptomyces rimosus* 381
 - streptomycin 8
 - stroke 497
 - structure–activity relationships (SAR) 49, 86
 - structure-based organic synthesis (SOS) 570–571
 - sugar–polyketide hybrids. *see* angucyclines
 - sulbactam 10
 - sulfated L-Choi core 338
 - sulfonamide inhibitors 353
 - sumerians 226
 - surotomycin 17, 18
 - Suzuki reaction 50, 63
 - Suzuki cross-coupling, with aryl triflate 309
 - Synercid® 20
 - synthetic oxazolidinones 595
- t**
- tagging approach 58, 59
 - directed sorting 59
 - synthesis of taxol analog library using 59
 - total synthesis of mappicines 58
 - taxanes
 - agents based on taxane scaffold 83, 115
 - based antitubercular agents 158
 - based MDR reversal agents 155, 156
 - based regimens 151
 - cabazitaxel exhibited encouraging efficacy 153
 - family 128
 - as MDR-reversal agents 159
 - new applications 155
 - as antiangiogenic agents 156, 157
 - as antitubercular agents 157, 158
 - taxane-based MDR reversal agents 155, 156
 - phase II trial of ortataxel 154
 - resistance 153
 - taxoids
 - from 14 β -hydroxybaccatin III 148, 149
 - in clinical development 150
 - from 10-DAB 145–147
 - from 9-dihydrobaccatin III 149, 150
 - taxol 115, 128
 - analog library 59
 - cell cycle arrest, and apoptosis 132
 - chemical modifications 134, 135
 - in baccatin component 135
 - in C13 side chain 134, 135
 - clinical trials 127
 - derivatives 113
 - with modifications in ring C and larotaxel 138
 - discovery of 127
 - docetaxel analogs with oxetane isosteres 140
 - D-ring-modified 140
 - drug resistance 133
 - like mode of action 86
 - microtubule-binding kinetics 145
 - naturally occurring taxane family 129

- normal taxane skeleton 128
- prodrugs of 140, 141
- with modifications at C2 and C7 141
- sources and methods of production 129
- biotechnology processes 131
- clinical development 131
- extraction from yew trees 129
- semisynthesis 129, 130
- total syntheses 130, 131
- structural and chemical biology 141
- bioactive conformation 142–144
- structure-activity relationships (SAR) 133, 134
- Taxol® 4, 128
- taxol–tubulin complex 114
- Taxotere® 83, 150
- tazobactam 10
- T-cell 450
- TD-1792 16
- TD-6424 14
- tebipenem pivoxil 11
- telavancin 13, 14, 253
- telithromycin 19, 372, 595
- temsirolimus 28, 30
- N-terminal threonine residue (Thr1)
 - of protein 484
- terpenes 32
- terphenyl moiety 28
- Terramycin® 12
- 7-tert-butyltrimethylsilyl-10-hydroxy-camptothecin 201
- tesetaxel 154, 155
- Tethya crypta* 6
- tetracyclic β -ketoesters alkaloids 48
- tetracyclines 9, 381–385
 - acid-catalyzed epimerization 381
 - biosynthesis 382
 - biosynthetic engineering 385
 - future 385
 - biosynthetic enzymes 385
 - biosynthetic pathway
 - intermediates 382
 - tailoring enzymes 385
 - broad spectrum 381
 - chlorothricin biosynthetic pathway 385
 - chlortetracycline 381
 - commercial tetracycline analogs 385
 - crystal structures 381
 - derivatives 12, 13
 - DNA topoisomerase I 384
 - nonenzymatic cyclizations 383
 - OxyABCDJKNLITQ 384
 - heterologous expression 384
 - oxytetracycline 381
 - biosynthesis 382, 383
 - heterologous expression 381, 382
 - pathway 383
 - engineering challenges 383
 - pharmacokinetics 381
 - potent antibiotics 381
 - related compound biosynthetic pathway 384
 - resistance 381
 - salicylic acid 385
 - selected analogs, example 381
 - semisynthetic analogs 381
 - SF2575 family 384
 - structure 384
 - *Streptomyces aureofaciens* 381
 - *Streptomyces rimosus* 381
 - synthetic analogs 381
 - tigecycline 381
 - usage 381
- tetrahydrofuran (THF) 314, 324
- tetrabutylammonium fluoride 324
- thebaine 227
- Theonella* sp. marine sponge 342, 343
- thienamycin 11
- thio-benzodiazepines 28
- thiolactomycin 273, 274
 - FabF inhibitors 273
- thiophene 316
- thrombin
 - chlorodysinosin 342
 - crystal structure 349
 - stereoscopic view of 342
 - structure of 335
 - surface representation 335
- thrombin inhibitors
 - based on Argatroban 355
 - bicyclic peptide analogs 351
 - blood coagulation cascade (see blood coagulation cascade)
 - challenges 348–350
 - cyclic amides 352
 - dabigatran discovery 348
 - low molecular weight, generation 346
 - mimicking nature 346–348
 - peptide analogs 350–352
 - peptidomimetics 352–355
- tiamulin 254
- Tie-2 inhibitor 25
- tigecycline 13, 381
- TL 139 155
- TLC390 195, 196
- toluene 56, 66
- tomaymycin 22

- Top 1–DNA interaction 189
 - Top 1 inhibitors. *see* camptothecin; irinotecan; topotecan
 - topoisomerase
 - I and II 184, 185
 - mutation 189
 - peculiarities 186
 - Top V 186
 - topotecan 184, 190, 195
 - synthesis of 207
 - transition metal-catalyzed coupling
 - reactions 50
 - trastuzumab 154
 - triazacryptand fluorescent K^+ ion sensor 488
 - triazadione 31
 - 2,4,6-trichlorobenzoyl chloride 512
 - Trichostrongylus colubriformis* 379
 - triclosan 61, 273, 274
 - tricyclic benzomorphan 230
 - trifluoromethyl-methyldioxirane 88
 - trimethoprim–sulfamethoxazole 258
 - 7-trimethylsilylethyl camptothecin 200
 - trimethylsilyl (TMS) protection 312
 - Trost syntheses, of furaquinocins A, B, and E 466
 - Trypanosoma brucei* 61
 - D/L-tryptophan imines 49
 - α -tubulin 133, 142
 - tubulin–epothilone complex 114
 - tubulin modulators 83
 - tubulin mutations 84
 - tubulin-polymerizing/antiproliferative activity, of epothilones 113
 - tumor angiogenesis
 - inhibitors of 334
 - stimulation 552
 - tumor-targeted drug 159
 - tumor-targeted folate conjugate BMS-753493 85
 - type 2 diabetes mellitus (T2DM) 301
- u**
- ubiquitin protein ligase E3A (UBE3A) 190
 - underprivileged scaffolds 30, 31
 - urinary glucose excretion (UGE) 306, 307
- v**
- Valium^(R) 22
 - valnemulin 20
 - vancomycin 13, 14, 253, 259, 272
 - van der Waals interactions 277
 - VEGFR-2 inhibitor 24, 25
 - veratramine 546
 - Veratrum californicum* 545
 - VIC-105555 260, 262, 264
 - PK parameters 260
 - vinblastine 83, 127
 - vincristine 83, 155, 491
 - vinyl iodide 69, 92, 95, 100, 102, 112
 - vitamin K antagonists, usage 348
- w**
- Wagner–Meerwein-type reaction 549
 - Wilkinson's catalyst 549
 - Wittig olefination 60, 259, 286, 287
 - Wittig reaction 63, 98, 100, 104
 - Wnt synergistic activators 57
 - Wolbachia pipientis* 378
- x**
- xanthate 287
 - X–Arg residues, for first-generation thrombin inhibitors structures 346
 - ximelagatran 346, 347
 - x-ray crystal structures
 - DH domains 370
 - docetaxel 141
 - ertugliflozin L-pyroglutamic acid cocrystal 323
 - human Top 1–DNA cleavable complex 187
 - oscillarin 340
 - phlorizin 304
 - salinosporamides 386
 - XRP6258 153
 - XRP9881 153, 154
 - L-xylose 317
- y**
- Yamaguchi esterification 495, 501, 502, 513, 518
 - conditions 524
 - Yamaguchi macrolactonization 95, 105, 110–112, 496
 - yasmin 569, 570
 - Yersinia pestis* 18
- z**
- zithromax 569, 570
 - ZK-Epo 85, 104
 - Z olefin 88
 - zotarolimus 28, 30